Nkarta (NKTX) Depreciation & Amortization (CF) (2019 - 2026)
Nkarta's (NKTX) quarterly Depreciation & Amortization (CF) came in at $2.3 million in Q1 2026, up 1.78% year-on-year from $2.3 million in Q1 2025, and up 3.68% quarter-over-quarter from $2.3 million in Q4 2025.
Nkarta (NKTX) Depreciation & Amortization (CF) (2019 - 2026) Analysis & Trends
Nkarta's Depreciation & Amortization (CF) history runs 8 years deep, the most recent figure standing at $2.3 million for Q1 2026.
- On a quarterly basis, Depreciation & Amortization (CF) rose 1.78% year-over-year to $2.3 million in Q1 2026; TTM through Mar 2026 was $9.2 million, a 0.41% change from a year earlier, with the FY2025 full-year figure at $9.2 million, changed 0.45% from the prior year.
- Depreciation & Amortization (CF) rose to $2.3 million in Q1 2026 per NKTX's latest filing, from $2.3 million in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $2.3 million in Q3 2024 and bottomed at $610000.0 in Q1 2022.
- The 5-year median for Depreciation & Amortization (CF) is $2.3 million (2024), against an average of $1.7 million.
- Across the five-year window, Depreciation & Amortization (CF) soared 208.78% in 2023 and slipped 1.75% in 2025, its largest moves.
- Year by year, Depreciation & Amortization (CF) stood at $729000.0 in 2022, then surged by 208.78% to $2.3 million in 2023, then rose by 1.64% to $2.3 million in 2024, then declined by 1.35% to $2.3 million in 2025, then advanced by 3.68% to $2.3 million in 2026.
- Per Business Quant, the three latest NKTX Depreciation & Amortization (CF) figures stand at $2.3 million (Q1 2026), $2.3 million (Q4 2025), and $2.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 41.14 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 91,781.47 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.20 Mn |
| 10 | Nkarta | 170.79 Mn | 170.79 Mn | - | 2.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.34 Mn |
| Mar 31, 2026 | 2.34 Mn |
| Dec 31, 2025 | 2.26 Mn |
| Dec 31, 2025 | 2.26 Mn |
| Sep 30, 2025 | 2.31 Mn |
| Sep 30, 2025 | 2.31 Mn |
| Jun 30, 2025 | 2.33 Mn |
| Jun 30, 2025 | 2.33 Mn |
| Mar 31, 2025 | 2.30 Mn |
| Mar 31, 2025 | 2.30 Mn |
| Dec 31, 2024 | 2.29 Mn |
| Dec 31, 2024 | 2.29 Mn |
| Sep 30, 2024 | 2.35 Mn |
| Sep 30, 2024 | 2.35 Mn |
| Jun 30, 2024 | 2.26 Mn |
| Jun 30, 2024 | 2.26 Mn |
| Mar 31, 2024 | 2.26 Mn |
| Mar 31, 2024 | 2.26 Mn |
| Dec 31, 2023 | 2.25 Mn |
| Dec 31, 2023 | 2.25 Mn |